Episode 381: Molecular Heterogeneity in Urothelial Carcinoma and Determinants of Clinical Benefit to PD-L1 Blockade

Romain Banchereau, PhD, joins the show to discuss and debate this Cancer Cell paper on molecular subtypes in urothelial cancer and implications for checkpoint blockade.